CD8, CD4, CD3, and PD-(L)1 are promising immune markers in predicting PR, whereas tumor lesion glycolysis and metabolic tumor volume are potential 18F-FDG PET/CT features to predict PR and CR after nCRT in EC. The gene discussed is CD8A; the disease is neoplasm.